SESSION I – NUTS AND BOLTS OF IMPLEMENTING MASS SPECTROMETRY TESTING MS or no MS: That is the Question Paul J. Jannetto, PhD, MT(ASCP), DABCC Mayo Clinic (Rochester, MN) Ross J. Molinaro, PhD, MT(ASCP), DABCC, FACB Emory University Hospital Midtown (Atlanta, GA) Post-analytic: Optimizing Post-implementation Monitoring Julianne C. Botelho, PhD Centers for Disease Control and Prevention (Atlanta, GA) SESSION II – SWEATING THE DETAILS Current Tools for Quantitative LC-MS in the Clinical Laboratory Deborah French, PhD, DABCC, FACB University of California San Francisco (San Francisco, CA) Considerations for Sample Preparation and Method Development Judy A. Stone, PhD, MT(ASCP), DABCC University of California San Diego (San Diego, CA) Making Sense of Numbers and Ratios: The Laboratory's Role in Pain Management Result Interpretation Frederick G. Strathmann, PhD, DABCC ARUP Laboratories (Salt Lake City, UT)
Toxicology/DAU Testing by Mass Spectrometry Kara L. Lynch, PhD, DABCC, FACB Immunosuppressant Testing by Mass Spectrometry James C. Ritchie, PhD, MPH, DABCC, FACB Emory University Hospital (Atlanta, GA) Vitamin D Testing by Mass Spectrometry Lorin M. Bachmann, PhD, DABCC Virginia Commonwealth University (Richmond, VA) Sex Hormone Testing by Mass Spectrometry Robert L. Fitzgerald, PhD, DABCC, FACB Best Practices for Maintaining Data Quality William A. Clarke, PhD, MBA, DABCC, FACB Johns Hopkins Hospital (Baltimore, MD) Beyond Westgard Rules: Quality Control for Mass Spectrometry Russell P. Grant, PhD, FACB Clinical Consultation and Results Reporting Majid Moridani, PharmD, PhD AIT Laboratories (Indianapolis, IN) Technological Innovation and Growth of Liquid Chromatography and Mass Spectrometry for Research in the Clinical Laboratory Agilent Technologies (Wilmington, DE) Data Management and Your Mass Spec Platform
Randall K. Julian, Jr., PhD Indigo Biosystems, (Indianapolis, IN) Future of Mass Spectrometry in Clinical Research – Discovery to Routine Bradley Hart, (Thermo Fisher Scientific) Factors Driving Implementation of Mass Spectrometry Tools in the Clinical Lab AB SCIEX (Gardner, KS)Skip to Main Content With more than 70 chapters and offices across the country, it’s easy to find and join a local Cystic Fibrosis Foundation chapter near you. ARCHIVED: NOT AVAILABLE FOR CREDIT Calcium Homeostasis and Vitamin D: What Are Vitamin D Tests Actually Measuring? The lecture will review basic calcium homeostasis, with an emphasis on how Vitamin D is involved in the regulation. The health benefits and risks of Vitamin D supplementation will be discussed, including current recommendations. A summary of strengths and weaknesses of the currently available test methods, from immunoassay to mass spectrometry, will be discussed. In addition, the use of certified reference materials and proficiency testing materials and their contribution to method harmonization will be outlined.
Originally presented on October 30, 2014 in Salt Lake City, Utah. Joely A. Straseski, PhD, MS, MT(ASCP), DABCC Medical Director, Endocrinology Laboratory, ARUP Laboratories Assistant Professor of Pathology, University of Utah School of Medicine Dr. Straseski is a medical director of endocrinology at ARUP and an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in pathology and laboratory medicine and a master of science in bacteriology from the University of Wisconsin-Madison, where she also served as a postdoctoral associate in the Department of Pathology. Dr. Straseski completed a postdoctoral fellowship in clinical chemistry at the Johns Hopkins Medical Institutions in Baltimore, Maryland. She has previously been awarded the Past-Presidents’ Scholarship by the American Association for Clinical Chemistry, as well as a Distinguished Abstract Award from the National Academy of Clinical Biochemistry. Dr. Straseski is board certified in clinical chemistry by the American Board of Clinical Chemistry.
After this presentation, participants will be able to: Review Vitamin D actions and the implications of deficiency. Compare and contrast current methods for measuring 25-hydroxyvitamin D. Examine the current state of method harmonization and future efforts in this area. University of Utah School of Medicine, Department of Pathology, and ARUP LaboratoriesThe U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.Avoid in people with known allergy or sensitivity to vitamin D, any similar compounds, or any part of the formula. Vitamin D is likely safe when taken by mouth in doses of 100 micrograms of vitamin D3 daily (4,000 IU) and when applied to the skin alone or in combination with corticosteroids for up to three months.
Vitamin D is possibly safe when taken by mouth or injected into the muscle in doses of 300,000 IU three times a year for vitamin D deficiency. Vitamin D may cause allergic skin reactions (inflammation, irritation, rash, and thinning), build-up of calcium in the arteries, changes in cholesterol levels, daytime sleepiness, excessive vitamin D levels, hardening of the arteries, headaches, increased calcium excretion or levels, increased risk of falls and fractures, increased risk of heart attack and stroke, increased risk of high blood pressure during pregnancy, increased risk of urinary tract infection, kidney or urinary stones, muscle pain, respiratory tract infection, and stomach problems (constipation, cramps, diarrhea, upset stomach, and vomiting). Vitamin D may affect blood sugar levels. Caution is advised in people with diabetes or low blood sugar, and in those taking drugs, herbs, or supplements that affect blood sugar. Blood sugar levels may need to be monitored by a qualified healthcare professional, including a pharmacist, and medication adjustments may be necessary.
Vitamin D may affect blood pressure. Caution is advised in people with blood pressure disorders or those taking drugs or herbs and supplements that affect blood pressure. Use cautiously in people with headaches, heart disease, immune disorders (including lymph cancer and tuberculosis), kidney disease, liver disease, lung disorders, musculoskeletal disorders, skin disorders, stomach disorders, and thyroid disorders. Use cautiously in pregnant women at risk of high blood pressure associated with pregnancy. Use cautiously in breastfeeding women. Avoid in people with known allergy or sensitivity to vitamin D, any similar compounds, or any part of the formula. Avoid in people with abnormal calcium excretion or levels. Use cautiously in pregnant women at risk of high blood pressure associated with pregnancy. The recommended adequate intake for pregnant women is the same as for non-pregnant adults. Most prenatal vitamins provide 400 IU of vitamin D daily as cholecalciferol, while high-risk populations may benefit from higher amounts (2,000-4,000 IU daily).